Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3274590 | 0.93 | S1PR1 (0.50) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3275517 | 0.89 | S1PR1 (0.42) | S1PR1S1PR5 | |
| SCHEMBL27762748 | 0.78 | S1PR1 (0.47) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3089144 | 0.73 | S1PR1 (0.50) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3275084 | 0.72 | S1PR1 (0.59) | S1PR1 | |
| SCHEMBL19639398 | 0.70 | S1PR1 (0.52) | S1PR1S1PR3S1PR5 | |
| SCHEMBL20597861 | 0.69 | S1PR1 (0.80) | S1PR1 | |
| SCHEMBL3274365 | 0.67 | SMN1; SMN2 (0.46) | — | |
| SCHEMBL20597867 | 0.66 | S1PR1 (1.00) | S1PR1 | |
| SCHEMBL20597955 | 0.66 | S1PR1 (1.00) | S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087491-A1 | POLYCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | disclosed |
| EP-2081916-A1 | OXADIAZOLE DERIVATIVES WITH ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE PROPERTIES | Novartis AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008037476-A1 | OXADIAZOLE DERIVATIVES WITH ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE PROPERTIES | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087491-A1 | POLYCYCLIC COMPOUNDS | CD4, HLA-DRB1, MALT1 | S1PR1 357/4885S1PR3 493/4885S1PR5 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.